Sorafenib Side Effects

Sorafenib (Sorafenib) is a kinase inhibitor drug with the trade name Nexavar. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary renal cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD-positive AML and radioactive iodine-resistant advanced thyroid cancer.

Based on clinical data, the most common adverse reactions in patients treated with sorafenib for hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid cancer (≥20%) include diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pain, hypertension, and bleeding. After marketing, adverse events include thrombotic microangiopathy, Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN), angioedema, rhabdomyolysis, osteonecrosis of the jaw, interstitial lung disease-like events, arterial (including aorta) aneurysms, dissections and ruptures.

SorafenibThe original drug has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around RMB 1,200. The original drug of sorafenib has also been launched overseas, and there are also sorafenib generic drugs produced in other countries. The specifications produced by Bangladesh Pharmaceutical FactoryThe price of 0.2g*60 tablets is around 450 yuan (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.